Helix BioPharma Corp. Announces New Director Appointment

AURORA, ON–(Marketwired – Sep 7, 2016) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix.

Dr. Witek brings over three decades of clinical development, medical affairs and commercial experience to Helix’s board. Dr. Witek currently holds the position of Senior Vice President, Corporate Partnerships and Chief Scientific Officer of Innoviva Inc. Dr. Witek is also a Professor & Senior Fellow at the Institute of Health Policy, Management & Evaluation at the Dalla Lana School of Public Health, University of Toronto.

Previously, Dr. Witek served as President and Chief Executive Officer, Boehringer Ingelheim Canada Ltd. Joining Boehringer in 1992, Dr. Witek held a number of positions of increasing responsibility. In 2001, he moved to Germany to lead the operating team for Spiriva^® where he also served as the Boehringer Ingelheim Co-chair of the Joint Operating Committee with Pfizer in their global alliance. During his tenure in Canada, Dr. Witek served on the Board of Directors at Innovative Medicines Canada (formerly Rx&D), Canada’s National Association for Research-Based Pharmaceutical Companies, chairing its Health Technology Assessment Committee and Public Affairs Committee. He also served over ten years on the Drug/Device Discovery and Development Committee of the American Thoracic Society, serving as Chairman from 2010 to 2012.

Dr. Witek holds a Doctor of Public Health degree from Columbia University, a Master of Public Health from Yale University, and a Master of Business Administration from Henley Management College.

“Ted’s robust clinical, regulatory and medical affairs experience will add tremendous depth to Helix’s board of directors,” said Dr. Sven Rohmann, Chief Executive Officer of Helix.

About L-DOS47

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Forward-Looking Statements and Risks and Uncertainties

This news release may contain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, including, without limitation, those relating to Helix’s operations and strategy, its research and development activities. Forward-looking statements, which may be identified by words including, “without limitation”, “believe”, “subject to”, “will“, “should“, “may”, “promising”, “developing” and other similar expressions, are intended to provide information about management’s current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include those described in Helix’s most recent Annual Report, including under the headings “Forward-Looking Statements” and “Risk Factors”, filed under Helix’s profile on SEDAR at www.sedar.com (together, the “Helix Risk Factors”). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix’s actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix’s management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.